We propose that all cutaneous melanomas with Breslow depth >4 mm regardless of ulceration (pT4a/b), or with disseminated disease (including satellitosis, in-transit metastasis, positive lymph node status, distant cutaneous and extra-cutaneous metastases including occult metastases) be tested for BRAF activating mutations (including non-V600), KIT and NRAS mutations using, RT-PCR, MALDI-TOF MS or NGS (Figure 1). This evidence concerns the gene NRAS and cutaneous melanoma.